Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 13 Issue 2, February 2007

In this issue (p 204) Cohn et al. show that excess TGF-β signaling is associated with myopathy in mouse models of Marfan syndrome and Duchenne muscular dystrophy. They further demonstrate that treatment with either antibodies to TGF-β or the heart medication losartan leads to normalization of muscle architecture and function in vivo. The cover depicts muscle, stained for nuclear DNA (blue), myosin (red) and laminin-λ 1 (green), displaying regeneration in the Duchenne mouse model treated with losartan. Image courtesy of Ronald Cohn and Harry Dietz.

Volume 13 Issue 2

Subscribe

Editorial

  • Efforts are underway to modernize clinical trial standards and normalize regulations to facilitate international collaboration. But as the European Union's Clinical Trials Directive shows, a one-size-fits-all regulatory strategy may be easier to conceive than to implement.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Correspondence

Top of page ⤴

Book Review

Top of page ⤴

News & Views

  • A drug commonly used to treat high blood pressure shows promise as a treatment in mouse models of Marfan syndrome and muscular dystrophy (pages 204–210).

    • Jeffrey S Chamberlain
    News & Views

  • An orally available drug enters the brain and interferes with signaling of orexin neuropeptides—providing a potential treatment for sleep disorders and possibly addiction (pages 150–155).

    • Thomas E Scammell
    • Clifford B Saper
    News & Views

  • The nuclear hormone receptor LXR—best known for sensing cholesterol metabolites—also responds to glucose. The findings give LXR a central role in modulating the body's response to metabolic inputs.

    • Joseph T Rodgers
    • Pere Puigserver
    News & Views

  • The ability to visualize brain pathology in living individuals with Alzheimer disease could change how the disease is diagnosed and drugs to treat it tested. A recently developed positron emission tomography tracer helps to image fibrillar amyloid-β and neurofibrillary tangles and brings us closer to this goal.

    • Mony J de Leon
    • Lisa Mosconi
    • Jean Logan
    News & Views

  • A new approach to treating leaky blood vessels emerges from a proteomic analysis. The findings have implications for diabetic retinopathy and other diseases associated with increased vascular permeability (pages 181–188).

    • Thomas W Gardner
    • David A Antonetti
    News & Views

  • An inhibitor of the Wnt signaling pathway mediates bone destruction in inflammatory arthritis. The inhibitor may be the key to understanding why in some joint diseases bone is destroyed and in others built up (pages 156–163).

    • Steven R Goldring
    • Mary B Goldring
    News & Views
Top of page ⤴

Research Highlights

Top of page ⤴

Review Article

Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Technical Report

Top of page ⤴

Corrigendum

Top of page ⤴

Search

Advanced search

Quick links